Kumar Srinivasan
Direktor/Vorstandsmitglied bei TRANSCENTA HOLDING LIMITED
Vermögen: 6 943 $ am 30.04.2024
Profil
Kumar Srinivasan is currently the President & Chief Executive Officer at Wugen, Inc. He is also a Director at Pulmotect, Inc. and an Independent Non-Executive Director at Transcenta Holding Ltd.
Previously, he worked as the Chief Business Officer & Executive Vice President at Turning Point Therapeutics, Inc. Dr. Srinivasan holds a doctorate degree from Case Western Reserve University, undergraduate and graduate degrees from the University of Madras, and an MBA from The University of Chicago Booth School of Business.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
06.04.2023 | 30 000 ( 0,01% ) | 6 943 $ | 30.04.2024 |
Aktive Positionen von Kumar Srinivasan
Unternehmen | Position | Beginn |
---|---|---|
TRANSCENTA HOLDING LIMITED | Direktor/Vorstandsmitglied | 19.12.2022 |
Pulmotect, Inc.
Pulmotect, Inc. BiotechnologyHealth Technology Pulmotect, Inc. develops clinical stage, novel, pathogen-agnostic, inhaled compound for the prevention and early treatment of acute, severe viral and bacterial respiratory infections. It provides safe, broad-spectrum, fast-acting protection against bacterial pneumonia (including MRSA), influenza, fungal pneumonia, and Class A bioterror agents (including anthrax, tularemia, and plague). The company was founded by Brenton Scott and Magnus Hook in 2007 and is headquartered in Houston, TX. | Direktor/Vorstandsmitglied | - |
Wugen, Inc.
Wugen, Inc. Packaged SoftwareTechnology Services Wugen, Inc. develops CAR-T therapy platform for cancer therapies. The company was founded by Matthew Cooper and John F. DiPersio and is headquartered in St. Louis, MO. | Vorstandsvorsitzender | 13.03.2023 |
Ehemalige bekannte Positionen von Kumar Srinivasan
Unternehmen | Position | Ende |
---|---|---|
TURG POIN | Corporate Officer/Principal | - |
Ausbildung von Kumar Srinivasan
Case Western Reserve University | Doctorate Degree |
The University of Chicago Booth School of Business | Masters Business Admin |
University of Madras | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
TRANSCENTA HOLDING LIMITED | Health Technology |
Private Unternehmen | 3 |
---|---|
Turning Point Therapeutics, Inc.
Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
Pulmotect, Inc.
Pulmotect, Inc. BiotechnologyHealth Technology Pulmotect, Inc. develops clinical stage, novel, pathogen-agnostic, inhaled compound for the prevention and early treatment of acute, severe viral and bacterial respiratory infections. It provides safe, broad-spectrum, fast-acting protection against bacterial pneumonia (including MRSA), influenza, fungal pneumonia, and Class A bioterror agents (including anthrax, tularemia, and plague). The company was founded by Brenton Scott and Magnus Hook in 2007 and is headquartered in Houston, TX. | Health Technology |
Wugen, Inc.
Wugen, Inc. Packaged SoftwareTechnology Services Wugen, Inc. develops CAR-T therapy platform for cancer therapies. The company was founded by Matthew Cooper and John F. DiPersio and is headquartered in St. Louis, MO. | Technology Services |